Hind.Organ.Chem. (500449)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Latest quarter sales of ₹147 Cr provides a meaningful revenue base despite the loss.
• Profit growth of +89.81% implies a large reduction in losses from the prior comparable period.
• Piotroski F-Score of 5/9 is not zero; it suggests some fundamental signals are improving.
• A 52-week range of ₹21.05-₹56.50 demonstrates the market sees an operational catalyst.

Concerns

• Negative net profit (₹-4 Cr latest quarter) and P/E of 0.00 mean no earnings-based valuation support.
• ROE of -1355.31% and ROCE of -5.20% indicate serious capital erosion and value destruction.
• Sales growth of -10.85% and zero dividend provide no income or momentum cushion.
• Unavailable book value, debt/equity, and promoter holding weaken the Graham-style fundamental check.

AI Analysis

Let me begin with a confession: when I see a P/E of 0.00, I usually close the file. Hind.Organ.Chem. has a market cap of ₹393 Cr and a latest quarterly net loss of ₹4 Cr on sales of ₹147 Cr. That is no earnings base. The reported profit growth of 89.81% only tells me losses narrowed substantially from a disastrous earlier period; it does not turn a loss-making commodity chemical company into a compounding machine. Sales are still declining at -10.85%. ROE of -1355.31% and ROCE of -5.20% show that every rupee employed in the business is earning a negative return. With book value, debt/equity and promoter holding all unavailable, I cannot compute Graham's margin of safety or asset protection. The Piotroski score of 5/9 is mediocre, not compelling. The stock is at ₹56.50, the upper end of a ₹21.05-₹56.50 range; the market appears to be pricing in a turnaround before the numbers confirm it. Commodity chemicals are cyclical and generally have little pricing power; there is no wide-moat sleep-at-night quality. A smaller loss is positive, but as an investor I demand proof of sustained profitability, positive ROCE, and a cleaner balance sheet before paying 52-week-high prices. This may become a genuine turnaround, but the current risk/reward offers no margin of safety. I would rather miss the rally than risk permanent capital on a share whose earnings, book value, and governance data are incomplete. In short: wait, watch, and let the balance sheet earn my trust.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer